Research - San Francisco, California, United States
A new diagnostic biomarker for colorectal cancerSeal Biosciences is developing a new prognostic biomarker as a companion diagnostic (CDx) that can determine which patients should receive anti-EGF therapy in metastatic colorectal cancer.
Outlook
Nginx
WordPress.org
Google Font API
Mobile Friendly